Navidea Biopharmaceuticals is a commercial stage biotechnology company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing the precision-targeted Manocept™ platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio.
Recent Press ReleasesMore Press Releases >
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.